MR metabolomics of fecal extracts: applications in the study of bowel diseases
β Scribed by Tedros Bezabeh; Ray L. Somorjai; Ian C. P. Smith
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 295 KB
- Volume
- 47
- Category
- Article
- ISSN
- 0749-1581
- DOI
- 10.1002/mrc.2530
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
NMRβbased metabolomics is becoming a useful tool in the study of body fluids and has a strong potential to contribute to disease diagnosis. While applications on urine and serum have been the focus to date, there are a number of other body fluids that are readily available and could potentially be used for metabolomicsβbased disease diagnosis. One such body fluid is stool or fecal extract. Given its contact with and transient stay in the colon and rectum, stool carries a lot of useful information regarding the health/disease status of both the colon and the rectum. This could be particularly useful for the nonβinvasive diagnosis of colorectal cancer and inflammatory bowel diseaseβthe two bowel diseases that are very common and pose significant public health problems. Different methodological considerations including the collection of sample, the storage of sample, the preparation of sample, NMR acquisition parameters, experimental conditions and data analysis methods are discussed. Results obtained in the detection of colorectal cancer and in the differentiation of the two major forms of inflammatory bowel disease (i.e. ulcerative colitis and Crohn's disease) are presented. This is concluded with a brief discussion on the future of MR metabolomics of fecal extracts. Copyright Β© 2009 Crown in the right of Canada. Published by John Wiley & Sons, Ltd
π SIMILAR VOLUMES
Inflammatory bowel diseases (IBD) are chronic, heterogeneous, and multifactorial intestinal inflammatory disorders. Major challenges in IBD research include identification of major pathogenic alterations of genes/proteins as well as effective biomarkers for early diagnosis, prognosis, and prediction
Among the available fecal biomarkers for the diagnosis and monitoring of inflammatory bowel disease (IBD), only calprotectin and lactoferrin have translated into useful clinical tools. Lactoferrin can be detected using simple and cheap techniques and it has excellent stability in feces over a long p
To assist in the evaluation of inflammatory changes of the affected bowel, we classified the transabdominal ultrasonographic findings into types A-C. We compared the in vivo and in vitro sonographic images to the histopathologic findings of resected specimens. A total of 22 bowel specimens (five nor